IMNM
Immunome Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.77
+1.82%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$16.60
From 52W high−43.78%
Volume1.14M
Market cap$1.98B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$16.60
From 52W high
−43.78%
Volume
1.14M
Market cap
$1.98B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.8x
P/E (TTM)
—
RSI (14)
24.4
MomentumView details →
1D Return
+1.82%
YTD Return
−22.08%
SummaryUpdated Jun 1, 2026
Immunome, Inc. (NASDAQ:IMNM) is a biopharmaceutical company founded in 2006 and headquartered in Exton, Pennsylvania. The company went public in October 2020 and focuses on discovering and developing antibody-based therapeutics for treating cancer and infectious diseases. Immunome leverages its proprietary antibody discovery platform to identify novel therapeutic targets and develop treatments that harness the immune system's power to fight disease.
Similar companies
Latest newsMore news →
Immunome granted inducement awards consisting of options to purchase 120,900 shares of common stock and 7,200 restricted stock units.13d agoImmunome Inc. amended its license agreement with Bristol-Myers Squibb, paying $20.0 million in cash and issuing 4,425,487 shares of common stock to acquire patent rights related to varegacestat and AL101 and remove milestone and royalty obligations.14d ago